Disease/Infection News

RSS

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Phase I/II data on Baxter's Lyme disease candidate vaccine presented at NFID conference

Baxter International Inc. today announced Phase I/II data evaluating the safety and immunogenicity of its investigational Lyme disease candidate vaccine during the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research in Baltimore, Md.

From Baxter International Inc. 25 Apr 2013

LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care Initiative.

25 Apr 2013

FDA announces public-private partnership to identify counterfeit anti-malarial medicines with CD-3

The U.S. Food and Drug Administration today announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines, including falsified products, with the deployment of the FDA-developed Counterfeit Detection Device, called CD-3.

25 Apr 2013

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

On World Malaria Day, 25 April, WHO recognizes significant accomplishments in preventing and controlling malaria, including in high-burden countries in sub-Saharan Africa, but highlights the threat of antimalarial drug resistance in south-east Asia's Greater Mekong subregion, where an emergency response is now being launched.

25 Apr 2013

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Medivir AB today announces that Janssen-Cilag International NV today has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for simeprevir (TMC435).

25 Apr 2013

Dietary substitution of saturated fats enriched in MCT prevents liver disease

Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Sciences, led by Dr. Martin Ronis have determined that dietary substitution of saturated fats enriched in medium chain triglycerides (MCT) for polyunsaturated fat prevents the development of nonalcoholic fatty liver disease (NAFLD).

25 Apr 2013

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.

25 Apr 2013

WHO research team still unsure of H7N9 transmission routes

The WHO "has only a limited understanding of a deadly new form of avian flu that has killed 20 people and infected more than a hundred others, a team of researchers said on Monday, leaving unclear how the disease spreads and how virulent it could become," the Wall Street Journal reports.

24 Apr 2013

Supreme Court justices hear arguments in case challenging anti-prostitution pledge

"Supreme Court justices appeared divided on Monday as they considered a challenge to a law requiring non-profit organizations to adopt an anti-prostitution policy in order to obtain federal funding for HIV/AIDS programs abroad," Reuters reports (Hurley, 4/22).

24 Apr 2013

Research maps risk factors for transmission of animal brucellosis, BTB to humans

A new study at the Institute of Tropical Medicine in Antwerp analyses the impact of animal brucellosis and bovine tuberculosis on animals and people in urban, peri-urban and rural Niger.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Editorial, opinion piece respond to Supreme Court case challenging anti-prostitution pledge

The U.S. Supreme Court on Monday heard a case -- AOSI v. USAID -- challenging a 2003 federal statute that requires non-profit organizations to adopt an "anti-prostitution policy" in order to receive federal funding for HIV/AIDS programs abroad, on the grounds that it violates the First Amendment.

24 Apr 2013

Study identifies malaria parasite protein as potential new target for drug treatment to prevent malaria

Scientists have discovered how a protein within the malaria parasite is essential to its survival as it develops inside a mosquito. They believe their findings identify this protein as a potential new target for drug treatments to prevent malaria being passed to humans.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Disease/Infection News

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Phase I/II data on Baxter's Lyme disease candidate vaccine presented at NFID conference

LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

FDA announces public-private partnership to identify counterfeit anti-malarial medicines with CD-3

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Dietary substitution of saturated fats enriched in MCT prevents liver disease

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

WHO research team still unsure of H7N9 transmission routes

Supreme Court justices hear arguments in case challenging anti-prostitution pledge

Research maps risk factors for transmission of animal brucellosis, BTB to humans

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Editorial, opinion piece respond to Supreme Court case challenging anti-prostitution pledge

Study identifies malaria parasite protein as potential new target for drug treatment to prevent malaria

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

U.S. on the verge of potentially devastating epidemic of untreatable gonorrhea

Home-based health education about diseases most effective, finds study

Rapid Assessment of Malaria device provides faster, more accurate diagnostic test

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News